Patent 7528143 was granted and assigned to Targegen, Inc. on May, 2009 by the United States Patent and Trademark Office.
The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.